Exosome Drug Developer Capricor Therapeutics Inc (CAPR) is Initiated by ROTH Capital to Buy

Posted by: Exosome RNA Administrator in Industry News June 16, 2016 0 2,040 Views

from The Market Digest by Robert Westfall

Capricor Therapeutics Inc (CAPR) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 15, 2016.

Capricor Therapeutics Inc opened for trading at $3.31 and hit $3.54 on the upside on Tuesday, eventually ending the session at $3.54, with a gain of 3.81% or 0.13 points. The heightened volatility saw the trading volume jump to 21,499 shares. Company has a market cap of $64 M.

Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).